Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Isao_Teshirogi
|
| gptkbp:collaboratedWith |
gptkb:Roche
gptkb:ViiV_Healthcare |
| gptkbp:country |
gptkb:Japan
|
| gptkbp:focus |
infectious diseases
pain management metabolic disorders |
| gptkbp:founded |
1878
|
| gptkbp:founder |
Shonosuke Shionogi
|
| gptkbp:headquarters_location |
gptkb:Osaka,_Japan
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:ISIN |
JP3347200002
|
| gptkbp:listedOn |
gptkb:Nikkei_225
|
| gptkbp:netIncome |
¥110.2 billion (2023)
|
| gptkbp:notableProduct |
Crestor (rosuvastatin)
Xofluza (baloxavir marboxil) |
| gptkbp:numberOfEmployees |
5,553 (2023)
|
| gptkbp:products |
antibiotics
antiviral drugs prescription drugs HIV drugs |
| gptkbp:revenue |
¥426.7 billion (2023)
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4507
|
| gptkbp:subsidiary |
gptkb:Shionogi_Inc.
|
| gptkbp:website |
https://www.shionogi.com
|
| gptkbp:bfsParent |
gptkb:YEP-621
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shionogi & Co., Ltd.
|